NCT03079544View on ClinicalTrials.gov

Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients

CompletedOBSERVATIONAL
Enrollment

665

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Extranodal NK-T-Cell Lymphoma, Nasal Type
Interventions
COMBINATION_PRODUCT

L-Asparaginase or or Pegaspargase containing chemotherapy

Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.

Trial Locations (2)

100010

Lymphoma House086, Beijing

200092

Xinhua Hospital, Shanghai

All Listed Sponsors
lead

Rong Tao

OTHER

NCT03079544 - Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients | Biotech Hunter | Biotech Hunter